Cargando…
A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions
Programmed cell death protein 1 (PD-1) is a crucial anticancer target, but the relatively low response rate and acquired resistance to existing antibody drugs highlight an urgent need to develop alternative targeting strategies. Here, we report the palmitoylation of PD-1, discover the main DHHC enzy...
Autores principales: | Yao, Han, Li, Chushu, He, Fang, Song, Teng, Brosseau, Jean-Philippe, Wang, Huanbin, Lu, Haojie, Fang, Caiyun, Shi, Hubing, Lan, Jiang, Fang, Jing-Yuan, Xu, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
RSC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341464/ https://www.ncbi.nlm.nih.gov/pubmed/34458782 http://dx.doi.org/10.1039/d0cb00157k |
Ejemplares similares
-
Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
por: Yao, Han, et al.
Publicado: (2018) -
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
por: Wang, Yiting, et al.
Publicado: (2018) -
THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
por: Li, Chushu, et al.
Publicado: (2021) -
Rational design of a potent macrocyclic peptide inhibitor targeting the PD-1/PD-L1 protein–protein interaction
por: Miao, Qi, et al.
Publicado: (2021) -
Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
por: Wang, Yiting, et al.
Publicado: (2020)